Heron Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript
Hi, good morning. Welcome to the 21st Annual Needham Healthcare Conference. I'm Serge Belanger, one of the healthcare analysts at Needham. And we're happy to have for our next session, Heron Therapeutics. We have Barry Quart, the company's CEO; as well as John Poyhonen, the company's Chief Commercial Officer. So, gentlemen, I'll hand it off to you guys. Do you want to start providing I guess an overview of the company and where you are in the launch of ZYNRELEF?
Yeah, definitely happy to do that. Thanks, Serge. I appreciate the opportunity to be here. And so for those that are not familiar with Heron, we have three commercial products. Two of them are in the CINV space, chemotherapy-induced nausea and vomiting, and that we have two products of different mechanisms that are used together potentially or separately, CINVANTI and SUSTOL. And John will be able to give an update in terms of the commercial success of these products, but we have been
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |